ProBioGen today announces the expansion of both protein and virus manufacturing at its Berlin headquarters. This includes the commissioning of an additional 1000L-scale GMP production line for proteins as well as the completion of the construction phase of its virus manufacturing unit.

In the protein vertical, this strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development through to commercial manufacturing. Utilizing its CHO.RiGHT^? platform in combination with market-approved technologies such as the DirectedLuck^? transposase and the ADCC enhancement GlymaxX^?, ProBioGen reinforces its position as a reliable partner in the industry. With this investment the company strengthens its footprint in the market and is advancing its state-of-the-art facilities across two manufacturing sites.

In the viral vector arena, ProBioGen is building on a broad experience in developing proprietary viral manufacturing platforms to offer solutions that go beyond standard processes. The company provides tailored cell lines for producing viral vectors and virus-like particles (VLPs). This includes customized stable cell line development for lentiviral (LV) and adeno-associated virus (AAV) production, addressing the unique challenges of emerging therapeutic platforms and enabling the creation of next-generation therapies with precision and efficiency.

"These strategic initiatives mark a major milestone for us as we continue to grow and better fulfill our customer's needs", explained Dr. Alfred Merz, Chief Executive Officer at ProBioGen.

Highlights:

• Enhanced Capacity: ProBioGen is scaling up to meet the surging demand for biologics.

• Advanced Viral Manufacturing: Expanded services include robust process development, early risk detection, and GMP production up to 200L, paired with comprehensive analytics and regulatory support.

• Tailored Solutions: Proprietary technologies, such as the DirectedLuck^? transposase, the RIGHT^? cell line, and the AGE1.CR.pIX^? cell line ensure innovative, customized approaches for complex challenges.

ProBioGen's proven expertise in cell line development, process optimization, and GMP manufacturing positions it as the partner of choice for life science innovators worldwide. This expansion reflects the company's commitment to quality, innovation, and driving the future of biopharmaceutical manufacturing.

About ProBioGen

ProBioGen is a Berlin-based biotech company, so called Contract Development and Manufacturing Organization (CDMO) and technology provider that operates globally.
It specializes in developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines, applying proprietary technologies to improve product quality and features. It started in 1994 as a spin-off of Charité, a widely recognized hospital as one of the best in the world. 30 years later, almost 300 employees with a wealth of experience work at ProBioGen's three locations in Berlin.
Every day, they contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisitions. Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow.